ALEXANDRIA, Va., Nov. 25 -- United States Patent no. 12,478,584, issued on Nov. 25.
"Atomoxetine hydrochloride oral suspension and use thereof" was invented by Paul Sudhakar (Shawnee, Kan.) and Scott Boyer (West Chicago, Ill.).
According to the abstract* released by the U.S. Patent & Trademark Office: "An oral liquid suspension comprising atomoxetine or a pharmaceutically acceptable salt thereof is disclosed, formulated at a concentration of about 20 mg/mL for the treatment of attention-deficit/hyperactivity disorder (ADHD). The suspension includes a dual preservative system (methylparaben and sodium benzoate), sweeteners, pH buffers, suspending agents, co-solvents, flavorants, and colorants. The composition demonstrates bioequivalence to...